The discipline of materials science has most commonly been associated with the study of structural or functional materials for engineering applications, such as metals, ceramics, and composites, but there are now, increasingly, great opportunities involving applications to soft matter, including polymers, powders, and biomaterials. The emerging discipline of pharmaceutical materials science attempts to apply physical principles common in materials science to challenges in such areas as drug delivery, control of drug form, manufacture and processing of nanoscopic and microscopic particle systems, and the structure and properties of bulk powders and their assemblies (e.g., tablets) for use in pharmaceutical applications. In this issue of MRS Bulletin, we have attempted to capture a snapshot of this rapidly developing new area of materials research, in order to bring it to the attention of the wider materials science community.

Pharmaceutical cocrystals are crystalline molecular complexes containing therapeutic molecules. They represent an emerging class of pharmaceutical materials offering the prospect of optimized physical properties. This article highlights important opportunities and challenges associated with the design and synthesis of pharmaceutical cocrystals. Cocrystallization is first placed into context with the more established approaches to physical property optimization of polymorph, hydrate, and salt selection. A directed, intermolecular-interaction-based approach to cocrystal design is described. The enhancement of specific physical properties, such as dissolution rate and physical stability, is illustrated by summarizing several recent reports. Synthetic approaches to cocrystallization are considered; in particular, the selectivity and screening-related opportunities afforded by solid-state grinding and solvent-drop grinding methods are discussed. Finally, an outlook on future developments summarizes the growth potential in this field, especially with regard to targeted, informatics-driven cocrystal screening approaches.

The engineering of particles with customized properties optimized for dosage form manufacture (tablet, capsule, ointment, etc.) has long been a goal of the pharmaceutical industry. Particles can be designed through modification in the size, morphology, and packing arrangement of the solids. The most common approach in achieving this is through crystallization. In this bottom-up process, the two main steps, nucleation and crystal growth, both play a decisive role in shaping the quality of the final crystalline product. In this review, the role of nucleation and crystal growth in controlling particle properties is discussed, and examples are provided that demonstrate the variation in solid-state properties as a function of size, habit (morphology), and internal structure of the particles. In addition, the role of particle properties in product performance and dosage form development of pharmaceuticals is also discussed.

The emergence of micro- and nanoscale science and engineering has provided new avenues for engineering materials with macromolecular and even molecular-scale precision, leading to diagnostic and therapeutic technologies that will revolutionize the way healthcare is administered. Biomaterials have evolved from off-the-shelf products to materials designed with molecular precision to exhibit the desired properties for a specific application, often mimicking biological systems. Controlling interactions at the level of natural building blocks, from proteins to cells, facilitates the novel exploration, manipulation, and application of living systems and biological phenomena. In addition, polymer networks with precisely engineered binding sites have been created via molecular imprinting, where functional monomers are preassembled with a target molecule and then the structure is locked with network formation. Nanoscale science and engineering have accelerated the development of novel drug delivery systems and led to enhanced control over how a given pharmaceutical is administered, helping biological potential to be transformed into medical reality. Micro- and nanoscale devices have been fabricated using integrated-circuit processing techniques, enabling strict temporal control over drug release. The advantages of these microdevices include simple release mechanisms, very accurate dosing, the capability of complex release patterns, the potential for local delivery, and possible biological drug stability enhancement by means of storage in a microvolume that can be precisely controlled. In particular, the development of polymer systems that are able to interact with their environment in a thermodynamically responsive manner has led to novel intelligent biomaterials and applications. Intelligent biomedical materials can be used for the delivery of drugs, peptides, and proteins; as targeting agents for site-specific delivery; or as components for the preparation of protein or drug conjugates. These intelligent materials are attractive options as functional components in micro- and nanodevices because of the ease with which recognition and actuation properties can be precisely tailored. Recent developments in intelligent materials and nano- or microdevices for drug delivery systems are the emphasis of this review, which addresses the use of intelligent biomedical materials as carriers for the development of novel pharmaceutical formulations.

The emerging field of nanotechnology has an enormous potential contribution to make to the field of pharmaceutical materials science. The advantages of drug nanoparticles can be as simple as dissolution rate enhancement through increased surface area or as complex as targeted delivery through novel pathways. However, the application of many nanoscale technologies has been slow because of difficulties controlling the drug form with decreasing particle size and maintaining chemical and physical stability upon storage. Advancing beyond these limitations requires a unique understanding of both the material properties of the active ingredients as well as the physical chemistry of the nano-sized particle. This article will examine the current challenges facing the pharmaceutical industry in applying nanotechnology, with a focus on the deficiencies in understanding that need to be addressed to move forward.

Computational modeling is a ubiquitous technique in materials science, but until recently this approach has not been widely applied to the drug development process. The formation of particles, their kinematics, and their response to processing stresses are increasingly being studied using computational techniques (computational fluid dynamics and discrete element analysis). These computational techniques can be predictive tools to guide scientists who are designing pharmaceutical dosage forms with specific macroscopic properties. This article gives an overview of the types of computational methods that are used in pharmaceutical materials science and provides examples of their application to some problems from the literature and the authors' own work.

The following article is an edited transcript based on the plenary address given by Craig R. Barrett, chair of the board of Intel Corp., on April 19, 2006, at the 2006 Materials Research Society Spring Meeting in San Francisco. Since before the industrial revolution, technology has changed lives, opportunities, and economies. Similarly, the digital evolution has touched nearly every aspect of modern life and is reshaping economies around the world. As more and more of the world's people engage in the digital economy, both competition and opportunities will grow. Competitiveness in the global economy will be determined by how people and nations position themselves in the digital evolution. What lies ahead for us in the next 10 years? What new technologies will alter the technology landscape? What are the opportunities going forward, and how do we prepare? How can materials research and development help us to move forward faster?